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Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor
control deficits, which is associated with the loss of striatal dopaminergic neurons
from the substantia nigra. In parallel to dopaminergic denervation, there is an
increase of acetylcholine within the striatum, resulting in a striatal dopaminergic–
cholinergic neurotransmission imbalance. Currently, available PD pharmacotherapy
(e.g., prodopaminergic drugs) does not reinstate the altered dopaminergic–cholinergic
balance. In addition, it can eventually elicit cholinergic-related adverse effects. Here, we
investigated the interplay between dopaminergic and cholinergic systems by assessing
the physical and functional interaction of dopamine D2 and muscarinic acetylcholine
M1 receptors (D2R and M1R, respectively), both expressed at striatopallidal medium
spiny neurons. First, we provided evidence for the existence of D2R–M1R complexes
via biochemical (i.e., co-immunoprecipitation) and biophysical (i.e., BRET1 and
NanoBiT R©) assays, performed in transiently transfected HEK293T cells. Subsequently,
a D2R–M1R co-distribution in the mouse striatum was observed through double-
immunofluorescence staining and AlphaLISA R© immunoassay. Finally, we evaluated the
functional interplay between both receptors via behavioral studies, by implementing the
classical acute reserpine pharmacological animal model of experimental parkinsonism.
Reserpinized mice were administered with a D2R-selective agonist (sumanirole) and/or
an M1R-selective antagonist (VU0255035), and alterations in PD-related behavioral
tasks (i.e., locomotor activity) were evaluated. Importantly, VU0255035 (10 mg/kg)
potentiated the antiparkinsonian-like effects (i.e., increased locomotor activity and
decreased catalepsy) of an ineffective sumanirole dose (3 mg/kg). Altogether, our data
suggest the existence of putative striatal D2R/M1R heteromers, which might be a
relevant target to manage PD motor impairments with fewer adverse effects.
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INTRODUCTION
Parkinson’s disease (PD) is a common movement disorder that
is clinically characterized by motor control deficits, such as
bradykinesia, muscular rigidity, resting tremors, and postural
instability (Mhyre et al., 2012). Approximately, 1% of the
population older than 60 years is affected by PD. The major
pathophysiological PD hallmark is the loss of dopaminergic
neurons projecting from the substantia nigra pars compacta
(Hisahara and Shimohama, 2011; Dexter and Jenner, 2013),
which leads to dopamine (DA) depletion within the striatum.
L-3,4-dihydroxyphenylalanine (L-DOPA) is an effective DA
replacement strategy, which efficiently reverses motor control
deficits at the early stages of the disorder. However, long-
term L-DOPA therapy (>5–10 years) is commonly associated
with adverse motor complications, such as dyskinesia and
efficacy fluctuations, thus reducing the patient’s quality of life
(Jenner, 2003; Kalia and Lang, 2015). Currently, DA receptor
agonists (i.e., pramipexole and ropinirole) are considered the
first choice in PD therapy, as monotherapy or adjuvants to
L-DOPA (Fox et al., 2011; Fox et al., 2018). Again, these
agonists are effective at the early stages, but they eventually
fail reducing motor complications (Jenner, 2003; Hisahara and
Shimohama, 2011). Interestingly, before L-DOPA was extensively
prescribed, anticholinergics were the first-line therapeutics in
PD (Carlsson et al., 1957; Katzenschlager et al., 2003). The
cholinergic system plays a pivotal role in regulating striatal
functions by modulating the excitability of GABAergic medium
spiny neurons (MSNs), which constitute nearly 95% of the
striatal neuronal population (Lv et al., 2017). Nowadays,
anticholinergics (i.e., biperiden) are eventually used as adjuvant
drugs in PD management, besides their adverse effects (i.e.,
nausea, cognitive impairments, dry mouth, urinary retention,
and blurred vision). Importantly, some of these adverse effects
are likely due to a lack of muscarinic acetylcholine receptor
(mAChR) subtype selectivity, because both M2R and M3R are
blocked (Chen and Swope, 2007; Pedrosa and Timmermann,
2013). Recently, cholinergic modulation of striatal functions
has gained renewed interest because of the development of
compounds targeting specific mAChR subtypes (Xiang et al.,
2012; Shen et al., 2015; Ztaou et al., 2016; Lv et al., 2017;
Chambers et al., 2019).
Five distinct mAChR subtypes (M1R–M5R) have been
identified, which are classified into two groups, based on
pharmacological and molecular characteristics. The excitatory
M1-like receptors (M1R, M3R, and M5R) transduce their signals
via Gq/11 proteins, whereas the inhibitory M2-like receptors
(M2R and M4R) are coupled to Gi/o proteins (Zhang et al.,
2002; Bordia and Perez, 2019). All subtypes are present in
the striatum, with M1R and M4R being highly expressed and
modulating the excitability of GABAergic MSNs (Hersch et al.,
1994; Yan et al., 2001). In general, two types of MSNs have
been distinguished: (i) dopamine D2 receptors (D2Rs) expressing
MSNs (i.e., D2R-MSNs), which belong to the striatal indirect
pathway (Gagnon et al., 2017); and (ii) dopamine D1 receptors
(D1Rs) containing MSNs (i.e., D1R-MSNs) constituting the
striatal direct pathway. The D1R-MSNs express postsynaptic
M4Rs, whereas M1Rs are expressed by both D1R-MSNs and D2R-
MSNs. Thereby, within the striatum, tonically active cholinergic
interneurons (ChIs), which constitute 1% to 2% of the total
striatal neuronal population (Bolam et al., 1984; Pisani et al.,
2007), release acetylcholine (ACh) through widely arborizing
axons with large terminal fields that modulate the MSNs via M1Rs
and M4Rs (Graybiel, 1990; Mesulam et al., 1992; Contant et al.,
1996). Interestingly, the modulation of MSNs with a selective
M1R antagonist resulted in antiparkinsonian-like effects in a
number of rat models of movement disorders (Xiang et al.,
2012). In addition, the blockade of M1R, M4R, or ChI signaling
improved the motor functions in 6-hydroxydopamine–lesioned
mice (Ztaou et al., 2016). Furthermore, systemic administration
of scopolamine (a non-selective mAChR antagonist) modulated
the DA turnover and reduced D2R affinity of raclopride in
monkey brains (Tsukada et al., 2000). These studies suggest
an intense neuronal interaction between dopaminergic and
cholinergic systems, where normal motor functions may require
a fine-tuned and coordinated control (Di Chiara et al., 1994;
Calabresi et al., 2000; Zhang et al., 2002). The extent to which both
neurotransmission systems specifically integrate at a molecular
and/or functional level is of high interest for the development
of novel multimodal pharmacological therapies to manage PD
(Fuxe et al., 2012).
Here, we describe a novel interaction between the D2R and
M1R in the striatum, which may eventually harmonize with those
previously described for D2R (Cabello et al., 2009; Lukasiewicz
et al., 2010; Borroto-Escuela et al., 2013; Bonaventura et al., 2014;
Fernandez-Duenas et al., 2015; Rico et al., 2017; Vasudevan et al.,
2019). In addition, we evaluated the antiparkinsonian efficacy of
a combined D2R agonist (i.e., sumanirole) and M1R antagonist
(i.e., VU0255035) treatment using the reserpine animal model
of experimental parkinsonism. To our knowledge, this study is
the first to demonstrate a molecular interaction and a functional
interplay between D2R and M1R.
MATERIALS AND METHODS
Plasmid Construction
The plasmids pFLAG-D2R, pHA-M1R, pD2R-Rluc, pM1R-YFP,
and pEYFP were a kind gift of Dr. Kjell Fuxe (Karolinska
Institutet, Stockholm, Sweden). The sequence encoding the
human M1R (NM_000738.3) was polymerase chain reaction–
amplified using primers containing specific restriction sites
(HindIII and EcoRI, 5′-GCTTAAGCTTATGAACACTTCAG-3′
and 5′- TCGAGAATTCGCGCATTGGC-3′) and cloned into the
HindIII/EcoRI sites of the NanoBiT R© vector NB MCS1 (Promega,
Madison, WI, United States). The construct was verified by
restriction digest and Sanger sequencing (Eurofins Genomics,
Ebersberg, Germany). This resulted in the fusion of the split
NanoLuciferase (NL) fragment LargeBiT (LgBiT; 18 kDa) to the
C-terminus of M1R. The constructs of cannabinoid types 1 and
2 receptors (CB1R and CB2R, respectively) and D2R fused with
LgBiT or Small BiT (SmBiT; 1 kDa) were previously developed
and described by our research group (Cannaert et al., 2016;
Wouters et al., 2019a).
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Cell Culture and Transient Transfection
Human embryonic kidney 293T (HEK293T; American Type
Culture Collection, Manassas, VA, United States) cells were
maintained in Dulbecco modified Eagle medium (DMEM;
Thermo Fisher Scientific, Pittsburg, PA, United States)
supplemented with GlutaMAX, 10% fetal bovine serum (FBS;
Merck KgaA, Darmstadt, Germany), streptomycin (100 µg/mL),
and penicillin (100 µ/mL) in a controlled environment (37◦C,
98% humidity, and 5% CO2). Prior to transfection, cells were
cultured in 10-cm dishes (co-immunoprecipitation) or six-
well plates [Bioluminescence Resonance Energy Transfer1
(BRET1) and NanoLuciferase Binary Technology (NanoBiT R©)
assays] in 10 or 2 mL DMEM supplemented with 10% FBS,
respectively. The HEK293T cells were transiently transfected
using the polyethylenimine (Sigma-Aldrich, St. Louis, MO,
United States) method. In all assays, medium was refreshed with
DMEM+ 10% FBS after 5 h.
Co-immunoprecipitation
HEK293T cells were transfected with 5 µg of the constructs
containing pFLAG-D2R and/or pHA-M1R. When necessary,
5 µg of the empty vector pcDNA3.1 was co-transfected to
maintain a total amount of 10 µg DNA per 10-cm dish. After
48 h, cells were washed three times with ice-cold phosphate-
buffered saline (PBS; 1.47 mM KH2PO4, 8.07 mM Na2HPO4,
137 mM NaCl, 0.27 mM KCl with pH 7.2), harvested, and
centrifuged, after which the pellet was stored at −80◦C until
further use. The cells were homogenized in ice-cold 50 mM
Tris–HCl (pH 7.4) with the Polytron at setting six for two
periods of 10 s. Subsequently, the homogenates were transferred
to 1.5-mL Eppendorf and centrifuged at 12,000 × g for
30 min at 4◦C. Then, all supernatant was removed, and the
pellets were lysed in radioimmunoprecipitation assay (RIPA)
buffer [150 mM NaCl, 25 mM Tris–HCl (pH 7.5), 1% sodium
deoxycholate, 1% NP-40, and 0.1% sodium dodecyl sulfate
(SDS)], supplemented with freshly added protease inhibitors
(2.5 g/mL aprotinin, 1 mM PEFA-block, 10 g/mL leupeptin),
for 1 h while rotating at 4◦C. The samples were centrifuged at
12,000 × g for 20 min at 4◦C. Next, the supernatant of each
sample was transferred to a new Eppendorf, and the protein
concentrations were determined using the bicinchoninic acid
(BCA) assay (Pierce Biotechnology, Rockford, IL, United States).
Thereafter, all samples were diluted with RIPA buffer to
obtain equal protein concentrations with a final volume of
500 µL. An amount of 10% for each sample (i.e., lysate) was
denatured at 37◦C for 10 min in 4 × Laemmli [5% SDS, 50%
glycerol, 65 mM Tris–HCl (pH 6.8) and 0.2% bromophenol
blue], supplemented with freshly added 10% β-mercaptoethanol.
The lysates were loaded onto a 10% polyacrylamide 10-well
gel and resolved via SDS–polyacrylamide gel electrophoresis
(SDS-PAGE). Subsequently, the proteins were blotted onto a
nitrocellulose membrane (Amersham Protran 0.45 NC; GE
Healthcare Life Sciences, Freiburg, Germany) and subjected
to immunoblot analysis, as described below. The other 90%
of each sample [i.e., immunoprecipitates (IPs)] was used for
immunoprecipitation through adding 2 µg mouse anti-FLAG
antibody (clone M2; Sigma-Aldrich) or mouse anti-HA antibody
(clone 16B12; Abcam, Cambridge, United Kingdom). After 1.5 h
of rotation, 20 µL of washed immobilized Protein-A UltraLink R©
Resin (#53139; Thermo Fisher Scientific) was added to the
IPs, and the rotation continued for 1.5 h at 4◦C. Then, the
beads were washed three times with RIPA buffer supplemented
with the freshly added protease inhibitors. The proteins were
eluted and denatured from the beads by heating the samples for
10 min at 37◦C in RIPA buffer and 4 × Laemmli supplemented
with freshly added 10% β-mercaptoethanol. All IP eluates were
subjected to SDS-PAGE electrophoresis and immunoblotting, as
described above.
Immunoblots containing lysates or IPs were blocked in PBS
with Licor blocking buffer (1:1; LI-COR Biosciences, Lincoln,
NE, United States) at room temperature (RT) for 1 h. Then,
the immunoblots were incubated with rabbit anti-HA (1:2,000,
#GTX29110; Genetex, Irvine, CA, United States) or rabbit anti-
FLAG (1:1000, #PA1-984B; Thermo Fisher Scientific) antibodies
in 1:1 Licor blocking buffer-PBST (PBS with 0.05% Tween 20)
overnight at 4◦C. The blots were washed three times with
PBST for 10 min at RT. Next, the blots were incubated with
donkey anti–rabbit secondary antibodies (1:15,000), conjugated
to IRDye680RD or IRDye800CW (LI-COR Biosciences), for 1 h
at RT. After incubation, the blots were washed three times with
PBST and two times with PBS, each for 10 min at RT, protected
from the light. Protein bands were visualized by the Odyssey
imaging system (LI-COR Biosciences).
Bioluminescence Resonance Energy
Transfer1 Assay
HEK293T cells were transfected with a constant amount of
pD2R-Rluc (200 ng) and increasing amounts of pM1R-YFP
or pEYFP (0–1,000 ng). Equal DNA ratios were maintained
with co-transfection of the empty vector pcDNA3.1, which
equilibrated the total amount of transfected DNA. Forty-
eight hours posttransfection, the cells were washed three times
with PBS, detached, and resuspended in Hanks balanced salt
solution (HBSS; Thermo Fisher Scientific). An aliquot was
used to determine the protein concentrations via the BCA
assay, to control the number of cells. All cell suspensions
were diluted to a density corresponding to a final protein
concentration of 600 ng/µL. Cell suspensions (corresponding
to 20 µg protein) were distributed in duplicates into white
and black 96-well microplates (#3600 and #3650; Corning,
Stockholm, Sweden) for BRET1 and fluorescence measurements,
respectively. The substrate, h-coelenterazine (Molecular Probes,
Eugene, OR, United States), was added at a 5 µM final
concentration. After 1 min (BRET1) and 10 min (Rluc total), the
signals were measured using the ClarioSTAR microplate reader
(BMG Labtech, Ortenberg, Germany) through the sequential
integration of signal detection at 475 nm (445–505 nm) and
530 nm (500–560 nm). The net BRET1 ratio was expressed as a
ratio of the light intensity at 530 nm over 475 nm by subtracting
the background signal, which was detected when D2R-Rluc was
only expressed with pcDNA3.1. The BRET1 curve was obtained
by fitting the data points to a non-linear regression equation
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assuming a single binding site using GraphPad Prism version 6.00
(San Diego, CA, United States).
NanoLuciferase Binary Technology R©
Assay
HEK293T cells were transfected with constructs encoding for
pM1R-LgBiT (200 ng) and pD2R-SmBiT (200 ng). As negative
controls, the cells were transfected with a combination of pM1R-
LgBiT and pCB1R-SmBiT or pD2R-SmBiT and pCB2R-LgBiT,
each with DNA concentrations of 200 ng. The functionality of
the CB1R-SmBiT and CB2R-LgBiT constructs was demonstrated
before (Cannaert et al., 2016). In all conditions, the construct
encoding for the fluorescent protein Venus was co-transfected
(5% of the total DNA transfected). The NanoBiT R© assay was
performed as described previously (Wouters et al., 2019a).
Briefly, 48 h posttransfection, the cells were washed two times
with PBS, detached, and centrifuged for 5 min at 1,000g at RT.
Protein concentrations were determined on an aliquot via the
BCA assay, and cell suspensions, normalized for cell number
(via a corresponding protein concentration of 600 ng/µL), were
diluted in HBSS. Following a 20-fold dilution of the Nano-Glo R©
Live Cell reagent (#N2011; Promega) containing the luminescent
substrate furimazine in aqueous Nano-Glo LCS dilution buffer,
25 µL of the diluted substrate was added to the wells of a
96-well plate containing 100 µL cell suspension. Fluorescence
(508–548 nm) or luminescence (440–480 nm) emission was
measured with the ClarioSTAR microplate reader in black or
white 96-well plates (#3650 and #3600; Corning), respectively.
The luminescence data were normalized for the measured
fluorescence signals to avoid signal fluctuations due to variations
in transfection efficiencies.
Animals
Caesarean derived 1 (CD-1) mice (Janvier Labs, Le Genest-
Saint-Isle, France), D2R knockout (D2R KO) CD-1, and M1R
knockout (M1R KO) C57BL/6J mice were generated as described
previously (Fisahn et al., 2002; Taura et al., 2017). Animals were
housed and tested in compliance with the guidelines described
in the Guide for the Care and Use of Laboratory Animals (Clark
et al., 1997) and following the European Communities Council
Directive (2010/63/EU), FELASA, and ARRIVE guidelines. The
animals were conventionally housed in groups of four or five in
a temperature-controlled (22◦C) and humidity-controlled (66%)
environment under a 12-/12-h light–dark cycle, where food and
water intake was ad libitum. The study protocol was approved by
the Ethical Committee on Animal Use and Care of the University
of Barcelona (CEEA/UB). All efforts were made to minimize
animal suffering and the number of animals used in this study.
Behavioral tests were performed with wild-type (WT) mice aged
5 months, weighing 40 to 55 g, between 12:00 and 18:00.
Double Immunofluorescence Staining
M1R KO mice were kindly provided by Dr. Adrian James Mogg
(Eli Lilly and Company Ltd., Windlesham, United Kingdom)
with permission of Dr. Jurgen Wess {National Institute of
Diabetes and Digestive and Kidney Diseases, National Institutes
of Health (NIH), Bethesda, MD, United States]. These mice
were anesthetized and perfused intracardially with 50 to 200 mL
of ice-cold 4% formaldehyde solution (Sigma-Aldrich) in PBS.
Subsequently, the brains were postfixed in 4% formaldehyde
solution overnight at 4◦C. D2R KO and WT littermate fixed
mouse brains were a kind gift from Dr. Jean-Martin Beaulieu
(Centre de recherche en Santé Mentale de Québec, Québec,
QC, Canada). Coronal brain sections (50 µm) were made with
the Vibratome 1200S (Leica Lasertechnik GmbH, Heidelberg,
Germany). Finally, the slices were collected and stored in
antifreeze solution (30% glycerol, 30% ethylene glycol in PBS with
pH 7.2) at -20◦C until further processing. The coronal brain slices
of WT, D2R KO, and M1R KO mice were washed three times
with PBS and permeabilized with 0.3% Triton X-100 in PBS for
2 h at RT. Then, blocking was performed by incubating the slices
with washing solution (PBS with 0.05% Triton X-100) containing
5% normal donkey serum (NDS; Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, United States) for 2 h at
RT. Subsequently, the slices were incubated overnight at 4◦C
with rabbit anti-M1R polyclonal (1:300, #mAChR-M1-Rb-Af340;
Frontier Institute Co., Ltd., Shinko-nishi, Ishikari, Hokkaido,
Japan) and guinea pig anti-D2R polyclonal (1:300, #D2R-
GP-Af500; Frontier Institute Co., Ltd.) antibodies in washing
solution with 1% NDS. In parallel, overnight incubations of
WT brain slices only in washing solution served as additional
negative controls. After overnight incubation, the slices were
washed three times with washing solution containing 1% NDS
for 10 min at RT. Next, slices were incubated with Alexa
Fluor R© 488–conjugated donkey anti–guinea pig (1:400, #706-
545-148; Jackson ImmunoResearch Laboratories) and Cy3-
conjugated donkey anti–rabbit (1:400, #711-166-152, Jackson
ImmunoResearch Laboratories) antibodies in washing solution
with 1% NDS for 2 h at RT. Then, the slices were washed three
times with washing solution for 10 min at RT and stained with
4,6-diamidino-2-phenylindole (DAPI; 1 µg/mL, #D9542; Sigma-
Aldrich) for 15 min at RT. Finally, slices were washed twice with
washing solution, twice with PBS for 10 min at RT, and preserved
in Vectashield (#H-1000; Vector Laboratories, Burlingame, CA,
United States). Images were captured with a Zeiss laser scanning
microscope 880 (Carl Zeiss AG, Jena, Germany).
AlphaLISA R© Immunoassay
The AlphaLISA R© immunoassay was performed as previously
described (Fernandez-Duenas et al., 2019). Briefly, WT and D2R
KO animals were euthanized by cervical dislocation, followed
by dissection of striata on an ice-cold plate. Then, striatum
was rapidly homogenized in ice-cold 50 mM Tris–HCl (pH
7.4) with a Polytron at setting six for three periods of 10 s.
The homogenate was centrifuged at 1,000 × g for 10 min,
and the supernatant was transferred to a new Eppendorf. The
protein concentrations were determined with the BCA assay,
and the membrane fractions were centrifuged at 12,000 × g
for 30 min. The pellets were resuspended in assay buffer
[20 mM MgCl2, 130 mM NaCl, 0.2 mM EDTA, 0.1 mg/mL
saponin, and 0.5% immunoglobulin G (IgG)–free bovine serum
albumin] to a final protein concentration of 1.5 µg/µL. Donkey
anti–guinea pig IgGs (#706-005-148; Jackson ImmunoResearch
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Laboratories) were conjugated to the acceptor beads (#6762001;
Perkin Elmer, Waltham, MA, United States), according to the
manufacturer’s instructions. Subsequently, 10 µL of each striatal
membrane in assay buffer was distributed in triplicate into a white
384-well plate (384 Well Small Volume HiBase Microplates;
Greiner Bio-one, Kremsmünster, Austria) and stored for 1 h at
4◦C. Subsequently, the membranes were incubated with rabbit
anti-M1R polyclonal (10 nM, #mAChR-M1-Rb-Af340; Frontier
Institute Co., Ltd.) and guinea pig anti-D2R polyclonal (10 nM,
#D2R-GP-Af500; Frontier Institute Co., Ltd.) antibodies in assay
buffer overnight at 4◦C. In the WT-negative controls, only the
anti-M1R antibody was added, whereas the D2R KO–negative
controls were incubated with assay buffer overnight at 4◦C.
Next, acceptor beads (40 µg/mL) were added to each well for
1 h. Then, the anti–rabbit IgG alpha donor beads (40 µg/mL,
#AS105D; Perkin Elmer) were added and mixed with the acceptor
beads by pipetting up and down. Any prolonged light exposure
was avoided. Finally, after 1-h incubation, the donor beads
were excited (640–720 nm), and acceptor beads emission (597–
633 nm) was measured with the ClarioSTAR microplate reader.
Locomotor Activity Tests
Mice were administered subcutaneously (s.c.) with reserpine
(3 mg/kg; Sigma-Aldrich) or vehicle (saline with 5% Tween 20,
s.c.) 20.5 ± 2 h before the test. Then, mice were administered
with vehicle [saline with 5% dimethyl sulfoxide (DMSO) and
5% Tween 20, i.p.], sumanirole (1, 3, or 10 mg/kg, i.p.; Sigma-
Aldrich) and/or VU0255035 (10 mg/kg, i.p.; Tocris Biosciences,
Bristol, United Kingdom) 10 min before each locomotor activity
test. The mice were evaluated for drug-induced locomotor
activity as described previously (Taura et al., 2017). Briefly,
non-habituated mice were placed in the center of an activity
field apparatus (30 × 30 cm, surrounded by four 50-cm-high
black walls) equipped with a camera above to record activity.
Exploratory behavior of the animals was recorded for 85 min. The
distance traveled was analyzed using the Spot tracker function
from ImageJ (NIH). All locomotor activity tests were performed
in a sound attenuated room, illuminated by light of 15 lux.
After each trail, the apparatus was cleaned with 70% alcohol and
rinsed with water.
Horizontal Bar Test
Catalepsy was induced in mice by the administration of reserpine
(3 mg/kg, s.c.) overnight (20.5 ± 2 h). Vehicle, sumanirole
(1, 3, or 10 mg/kg, i.p.) and/or VU0255035 (10 mg/kg, i.p.) was
administered, and 1.5 h later, catalepsy was measured as described
previously (Massari et al., 2017; Taura et al., 2017). Briefly, using a
stopwatch with a cutoff time of 120 s, the duration of an abnormal
upright posture was measured, in which the forepaws of the
mouse were placed on a horizontal wooden bar (0.6-cm diameter)
that was located 4.5 cm above the floor.
Tremulous Jaw Movements
Mice were administered reserpine (3 mg/kg, s.c.) or vehicle
(saline with 5% Tween 20, s.c.). Subsequently, vehicle (saline with
5% DMSO and 5% Tween 20, i.p.), sumanirole (1-10 mg/kg,
i.p.), and/or VU0255035 (10 mg/kg, i.p.) was administered 1.5 h
before the test and 22 ± 2 h after reserpine treatment. The
tremulous jaw movements (TJMs) were measured with hand-
operated counters, as described previously (Massari et al., 2017).
Briefly, the mice were placed individually in a glass cylinder
(13-cm diameter) and allowed to habituate for 10 min. Mirrors
were placed under and behind the cylinder to allow observation
when the animal faced away from the observer. Tremulous jaw
movements were defined as rapid vertical deflections of the
lower jaw that resembled chewing, but were not directed to any
particular stimulus (Salamone et al., 1998). The incidence of these
oral movements was measured continuously for 10 min, but were
discounted during grooming.
Statistical Analysis
The number of biological replicates (n) in each experimental
condition is indicated in the figure legends. Data of behavioral
studies are expressed as the mean ± SEM; all the other data are
presented as the mean ± SD. Numerical data were imported to
GraphPad Prism version 6.00 for Windows (GraphPad Software,
La Jolla, CA, United States). Statistical analysis of cellular or tissue
data was performed using the Mann–Whitney U test or the non-
parametric analysis of variance (ANOVA) by ranks of Kruskal–
Wallis test followed by the Dunn multiple-comparisons post hoc
test. Normal distributions of the behavioral data were inferred
through the D’Agostino–Pearson normality test. Subsequently,
behavioral data were analyzed with the one-way ANOVA or
the two-way repeated-measures ANOVA followed by the Tukey
or Dunnett multiple-comparisons post hoc test. p ≤ 0.05 was
considered as statistically significant.
RESULTS
D2R–M1R Interaction in HEK293T Cells
The ability of D2R and M1R to physically interact in living
cells was assessed by biochemical and biophysical assays.
First, co-immunoprecipitation experiments were performed in
transiently transfected HEK293T cells. Interestingly, when HA-
M1R was immunoprecipitated from FLAG-D2R and HA-M1R
co-transfected HEK293T cells, a specific immunoreactive band
of 90 to 100 kDa corresponding to FLAG-D2R was detected
(Figure 1A, IPs). It is important to note that this band was not
observed when the cells were transfected with a single receptor
plus an empty plasmid or from an extract mix of separate
transfected cells. Moreover, the D2R and M1R constructs were
properly expressed in the whole setup (Figure 1A, lysates). These
results indicate that D2R and M1R are expressed within the same
membrane context and are prone to interact.
Subsequently, the existence of D2R–M1R complexes was
verified by means of BRET1 saturation assays. Accordingly,
HEK293T cells were co-transfected with a constant amount of
the D2R-Rluc construct and increasing concentrations of M1R-
YFP or YFP plasmids (Figure 1B). A positive BRET signal was
observed when D2R-Rluc and M1R-YFP were co-expressed, due
to the energy transfer between Rluc and YFP. Conversely, in
cells co-expressing D2R-Rluc and YFP, no BRET1 signal was
observed. Overall, the BRET1 data demonstrated that D2R and
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FIGURE 1 | D2R–M1R interaction in transiently transfected HEK293T cells. (A) Co-immunoprecipitation. HEK293T cells were harvested and lysed 48 h after
transfection. The lysates were used for immunoblotting (IB) with anti-FLAG and anti-HA antibodies to demonstrate D2R and M1R expression, respectively (left
panels). The rest of the samples (IPs) was subjected to immunoprecipitation with a mouse anti-HA antibody. The co-immunoprecipitate was confirmed via the
detection of FLAG-D2R upon IB with rabbit anti-FLAG and rabbit anti-HA antibodies (right panel; boxed lane). Data shown are representative of three independent
experiments. (B) BRET1 saturation curve. The BRET1 signal in HEK293T cells co-expressing a constant amount of D2R-Rluc and increasing amounts of M1R-YFP
(n = 5) or YFP (n = 3) constructs was measured 48 h posttransfection. The BRET1 saturation curve is derived from all independent experiments. (C) NanoBiT R©
complementation assay. The SmBiT and LgBiT parts of the NanoLuciferase fragments were fused to the C-terminus of the indicated receptor. The constructs were
overexpressed via transient transfection in HEK293T cells. Results are presented as mean ± SD (n = 3). Statistical significance was tested using the non-parametric
ANOVA by ranks of Kruskal–Wallis followed by the Dunn multiple-comparisons post hoc test, *p ≤ 0.05.
M1R are in close proximity (<10 nm), thus supporting the
existence of D2R–M1R complexes in living cells (Cottet et al.,
2012; Dacres et al., 2012).
Finally, we implemented the complementation-based
NanoBiT R© assay to further validate the D2R–M1R interaction
in HEK293T cells (Figure 1C). This assay utilizes two inactive
fragments of a split NL, which, when fused to two interacting
proteins, come into close proximity and reassemble into
a functional protein (Wouters et al., 2019b). As shown in
Figure 1C, co-expression of M1R and D2R fused to the large
and small subunits of a split NL (M1R-LgBiT and D2R-SmBiT,
respectively) yielded a high luminescent signal (Figure 1C) when
compared to HEK293T cells expressing either constructs for
M1R and CB1R (M1R-LgBiT + CB1R-SmBiT) or D2R and CB2R
(D2R-SmBiT + CB2R-LgBiT), as previously reported (Wouters
et al., 2019a). In addition, very low signals were observed in
cells expressing either M1R (19 ± 3.5) or D2R (9 ± 1.7), along
with HaloTag-SmBiT or HaloTag-LgBiT, respectively. Altogether,
our results are compatible with the formation of D2R/M1R
heteromer formation by ectopically expressed M1R and D2R
in HEK293T cells.
Co-distribution of D2R and M1R in the
Mouse Striatum
Once the existence of D2R–M1R complexes in a heterologous
expressing system was demonstrated, we aimed to verify whether
this interaction might also occur in native tissue. To this
end, we first analyzed D2R and M1R expression in mouse
striatum by double-immunofluorescence staining. The specificity
of the anti-D2R and anti-M1R antibodies was verified by using
striatal slices from D2R- and M1R-deficient mice (D2R KO and
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M1R KO, respectively) (Supplementary Figures S1 and S2).
High-magnification images of the dorsal striatum from WT
mice showed a high degree of D2R and M1R co-distribution
(Figure 2A, arrows). Subsequently, to further demonstrate a close
proximity (<200 nm) between both receptor types, we applied an
AlphaLISA R© immunoassay, as described previously (Fernandez-
Duenas et al., 2019). Briefly, striatal membrane extracts were first
incubated with specific primary antibodies against the receptor,
which can be recognized by secondary antibodies tagged with
beads able to engage in an energy transfer after the production
of a singlet oxygen (Fernandez-Duenas et al., 2019). A significant
higher energy transfer was observed in the WT compared to
its corresponding negative control [WT vs. WT (one Prim Ab);
p ≤ 0.05, Figure 2B]. In addition, analysis of striatal D2R KO
tissue did not result in a significant difference in signal with or
without adding primary antibodies (Figure 2B). These results
support the existence of the interaction (or at least the very
close proximity) between D2R and M1R in native tissue, namely,
the mouse striatum.
Multimodal D2R Agonist and M1R
Antagonist Treatment of Reserpinized
Mice
The data obtained in HEK293T cells and striatal slices support
the notion that D2R and M1R might physically interact in the
striatum. Therefore, we hypothesized that this receptor–receptor
interaction might constitute a molecular target for multimodal
pharmacological interventions finely controlling striatal motor
FIGURE 2 | Co-distribution of D2R and M1R in the mouse striatum. (A)
Double-immunofluorescence staining. Representative images of specific
immunoreactivities with anti-D2R and anti-M1R antibodies in the dorsal
striatum of wild-type (WT) CD-1 mice. Overlapping immunofluorescence
signals are indicated with arrows. Images shown are representative of two
independent experiments. Scale bar = 50 µm. (B) AlphaLISA R© immunoassay.
Specific signal obtained from striatal WT and D2R KO mice, with or without
adding one or two primary antibodies. Results are presented as mean ± SD
(n = 4). Statistical significance was tested using the Mann–Whitney U test,
*p ≤ 0.05.
activity. Accordingly, we tested the effects of a combined drug
treatment regimen (D2R agonist + M1R antagonist) in a well-
known model of movement disorder, i.e., the reserpinized mouse
(Leao et al., 2015; Leal et al., 2016). The drugs used were the D2R-
selective agonist sumanirole and the M1R-selective antagonist
VU0255035. Sumanirole was chosen as it shows 200-fold more
selectivity for D2R than for other DA receptors subtypes and as it
has been used both in human patients and animal models of PD
(McCall et al., 2005; Stephenson et al., 2005; Barone et al., 2007).
Similarly, the competitive orthosteric antagonist VU0255035 has
a 75-fold higher selectivity for M1R over other mAChR subtypes
(Sheffler et al., 2009). In addition, both compounds have already
been tested individually in reserpine-treated animals (McCall
et al., 2005; Xiang et al., 2012).
First, we evaluated the effects of the D2R agonist sumanirole.
Mice were treated with reserpine (3 mg/kg, s.c., overnight)
and, thereafter, with the selective D2R agonist. Interestingly,
sumanirole only promoted an increase in locomotion at the
highest dose (10 mg/kg) (Supplementary Figure S3). Similarly,
only at 10 mg/kg, sumanirole blocked the cataleptic effects
induced by reserpine, while a slight but non-significant reduction
of TJMs was observed (Supplementary Figure 3). Thus, based on
these data, we selected 3 mg/kg of sumanirole (i.e., subthreshold
dose) for further multimodal experiments in combination with
the M1R antagonist VU0255035. A dosage of 10 mg/kg of
VU0255035 was selected based both on a pilot study and its
pharmacokinetic profile. According to Sheffler et al. (2009),
10 mg/kg VU0255035 (i.p.) was sufficient to cross the blood-
brain barrier, with maximal M1R inhibition after 30 min, with
an elimination half-life of ∼2.5 h in the brain. In addition,
this concentration was also reported to not impair contextual
fear conditioning, a model for hippocampus-dependent learning
(Sheffler et al., 2009).
In animals that received the combined treatment with
VU0255035 and sumanirole (VU + SUM; 10 and 3 mg/kg, i.p.)
we observed a significant (p ≤ 0.05) reversal of the reserpine-
induced akinesia (Figure 3). In contrast, in none of the animals
treated with VU or SUM alone the akinetic status was reversed
(Figure 3A). Our findings suggest a fine balance in locomotor
activity between reserpine-induced akinesia and VU + SUM
treatment. It is interesting to note that the VU + SUM–
administered animals showed an increase in locomotor activity
after ∼25 min, which is in accordance with the pharmacokinetic
profile of VU (Figure 3B). Thus, significant differences in
locomotion were observed between the VU + SUM–treated
group compared to the groups receiving a single treatment.
In line with the results obtained while evaluating locomotion,
a significant reduction in reserpine-induced catalepsy was
observed in VU + SUM–treated mice compared to those that
were administered a single agent (Figure 3C). However, while
the simultaneous VU0255035 and sumanirole administration
reduced TJMs as compared to vehicle, when compared to
single administered animals, no differences were found with
VU0255035-treated reserpinized mice (Figure 3D). Therefore, a
low dose of sumanirole was unable to potentiate the VU0255035-
mediated TJMs reduction. This lack of sumanirole-mediated
potentiation of VU0255035 effect might be due to the fact
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FIGURE 3 | Effect of the combinatorial treatment of suboptimal dosages of sumanirole and VU0255035 on reserpine-induced motor disturbances in mice. Mice
treated with saline (control mice = Ctrl), VEH (saline with 5% Tween, i.p.), VU (VU0255035, 10 mg/kg, i.p.), SUM (sumanirole, 3 mg/kg. i.p.), or VU + SUM
(VU0255035, 10 mg/kg and sumanirole, 3 mg/kg, i.p.) after reserpine administration (3 mg/kg, s.c., 20.5 ± 2 h) were evaluated via the (A,B) locomotor activity test,
(C) horizontal bar test, and (D) for tremulous jaw movements (TJMs). (A) The total distance traveled (cm) was measured for 85 min. Results are presented as
mean ± SEM (n = 8–9 animals). Statistical significance was tested using one-way ANOVA followed by the Dunnett post hoc test with VEH, VU, and SUM compared
to VU + SUM animals, *p ≤ 0.05. (B) The distance traveled (cm) was measured every 5 min for 85 min. Results are presented as mean ± SEM (n = 8–9 animals).
Statistical significance was tested using two-way repeated-measures ANOVA followed by the Tukey post hoc test with VEH, VU and SUM compared to VU + SUM
animals, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. (C) Reserpine-induced catalepsy in mice evaluated via the horizontal bar test with a cutoff value of 120 s. Results
are presented as mean ± SEM (n = 8–13 animals). Statistical significance was tested using one-way ANOVA followed by the Tukey post hoc test with VEH, VU, and
SUM compared to VU + SUM animals, *p ≤ 0.05, ***p ≤ 0.001, and ****p ≤ 0.0001. (D) Reserpine-induced orofacial dyskinesia evaluated by TJM frequency for
10 min. Results are presented as mean ± SEM (n = 9–13 animals). Statistical significance was tested using one-way ANOVA followed by the Tukey post hoc test
with VEH, VU, and SUM compared to VU + SUM animals, **p ≤ 0.01.
that 10 mg/kg VU0255035 already induced a slight, but not
significant (p = 0.1712), reduction in TJMs. Of course, it would
be reasonable to speculate that M1Rs located within neuronal
circuits controlling distinct behavioral responses might have
different efficacies. Overall, our data support the use of low D2R
agonist doses in combination with an M1R antagonist as a novel
multimodal antiparkinsonian pharmacotherapy.
DISCUSSION
In the last years, G protein-couped receptor (GPCR) oligomers
have gained interest as novel putative targets for several diseases.
One of the most well-characterized D2R-containing oligomers
is the D2R/A2AR heteromer in the striatum, where reciprocal
antagonistic interactions both at the binding and effector levels
occur between these receptors (Ferré et al., 2018). Importantly,
this functional interplay grounded the utility of A2AR blockade
in PD treatment, which recently ended with the approval of
a selective A2AR antagonist, istradefylline (Nourianz), as an
adjuvant drug in PD treatment. Interestingly, while a variety of
D2R oligomer complexes has been described (Marcellino et al.,
2008; Trifilieff et al., 2011; Bonaventura et al., 2014; Borroto-
Escuela et al., 2014; Hasbi et al., 2017), few studies exist for
M1R (Goin and Nathanson, 2006; Hern et al., 2010). In the
present study, we have observed, for the first time, the existence
of striatal D2R and M1R complexes. In addition, we provide
data supporting a novel multimodal antiparkinsonian treatment,
consisting of the use of low D2R agonist doses in combination
with M1R antagonists. Thus, our results may prompt further
investigating these receptor complexes as interesting targets to
modulate dopaminergic neurotransmission in dopamine-related
diseases (i.e., PD) (Hersch et al., 1994; Surmeier et al., 2007;
Fuxe et al., 2012).
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As described for the D2R/A2AR heteromer, both M1R and
D2R are expressed at postsynaptic membranes of striatopallidal
MSNs. Thus, the avidity of D2R to heteromerize with a
named GPCR (i.e., A2AR, mGlu5R or M1R) within this
specific subcellular domain may depend on the absolute
expression of specific protomers and the relative affinities
shown for each receptor–receptor interaction. Importantly, the
density of each individual D2R containing oligomer may be
altered in disease conditions, which may constitute a putative
pathological fingerprint. Precisely, we recently reported that
D2R/A2AR heteromers would be increased in the caudate
from human postmortem PD patients (Fernandez-Duenas
et al., 2019). This fact would negatively affect dopaminergic
neurotransmission, thus providing the rationale for using
A2AR antagonists in PD (see above). Of note, whether the
decrease in heteromer formation is a cause or a consequence
of PD pathology, or even treatment, needs to be further
elucidated. Here, we demonstrated the existence of D2R–M1R
complexes in the striatum and its potential pharmacotherapeutic
usefulness using an animal model of PD. However, further
studies should be conducted to determine: (i) D2R/M1R
heteromer status in human PD striatum (i.e., increase or
decrease in the proportion of D2R and M1R protomers
forming homomers or heteromers) and (ii) the molecular
and functional interplay with other striatal D2R-containing
oligomers (i.e., D2R/A2AR heteromers). Certainly, establishing
the D2R-containing heteromer status in PD could determine
the design of selective combined pharmacotherapeutic strategies
restoring the unbalanced dopaminergic neurotransmission
associated with PD.
In our study, the functional interplay between D2R and
M1R was demonstrated by the co-administration of a D2R
agonist and an M1R antagonist to reserpinized mice, which is
an animal model mimicking parkinsonian motor and non-motor
impairments (Leao et al., 2015; Leal et al., 2016). The major
disadvantage of this model is the lack of dopaminergic neurons
degeneration and protein aggregation. Nevertheless, reserpine-
treated rodents have been successfully applied to predict
the efficacy of many dopaminergic and non-dopaminergic
drugs (e.g., benzotropine), which are clinically in use for
PD management. The high predictive validity of this model
results in the maintenance of its position as a valid choice to
discover novel therapeutics in an early preclinical stage (Duty
and Jenner, 2011). Other advantages are its low toxicity, low
cost, and its reproducibility among laboratories (Leao et al.,
2015). Furthermore, the reserpine animal model was one of
the first models used to demonstrate the therapeutic efficacy
of L-DOPA, which still remains the criterion standard in PD
therapy (Carlsson et al., 1957). Now, D2R selective agonists
are also included in the pharmacotherapeutic munition in PD
management. Of note, although the full D2R agonist sumanirole
has a high affinity for D2R, it also has a moderate affinity for
the serotonin 5-HT1A receptor (Ki = 95 nM) (Heier et al.,
1997; Wuts, 1999; McCall et al., 2005). However, according to
Weber et al. (2010), the suboptimal sumanirole concentration
applied in our study should not result in 5-HT1A receptor off-
target effects (Weber et al., 2010). It is worth mentioning that
our results, using a suboptimal concentration of sumanirole,
are not in line with the findings of another study, which
also used a reserpine animal model (McCall et al., 2005). The
discrepancy could be owing to differences in species (mice vs.
rats), reserpine inductions (3 mg/kg vs. 5 mg/kg + AMPT),
administration routes of sumanirole (i.p. vs. s.c.), and/or time
of reserpine pretreatments (20.5 vs. 18 h). Nevertheless, a
long-term effect in locomotion at high sumanirole doses was
demonstrated in both studies, which has been suggested to
be the result of postsynaptic D2R activation (McCall et al.,
2005). On the other hand, the administered dose of the
competitive orthosteric M1R antagonist VU0255035 results in
maximal receptor inhibition, with a high brain penetration
after 30 min, without impairment in hippocampus-dependent
learning tasks (Sheffler et al., 2009). The combined treatment
increased locomotor activity and decreased the time of catalepsy
and the amount of TJMs in our animal model, whereas the
reduction in TJMs was mostly due to the M1R antagonist (Lees,
2005; Pedrosa and Timmermann, 2013).
The dysregulation of dopaminergic or cholinergic systems
has been linked to movement disorders, such as dystonia,
Huntington disease, or PD (Pisani et al., 2007). Nowadays, at the
early stages, PD therapy is commonly initiated with D2R agonists,
which do not require carrier-mediated transport or produce
potentially toxic metabolites and free radicals (Hagan et al., 1997;
Jenner, 2003). However, D2R agonists may elicit severe adverse
effects such as valvular heart disease or psychiatric disturbances
(Lees, 2005; Hisahara and Shimohama, 2011; Pedrosa and
Timmermann, 2013), which are probably induced by activating
D3Rs and D4Rs (Rich et al., 1995; McCall et al., 2005). Despite its
high D2R selectivity, sumanirole has not demonstrated a clinical
improvement over ropinirole (Barone et al., 2007; Singer et al.,
2007). However, as suggested by the present study, sumanirole
remains a valuable tool in lead optimization, drug discovery,
and animal models, where the novel D2R–M1R interaction
may provide a rationale to target specific receptor subtypes
in the treatment of PD. In addition, reducing the amount of
D2R agonist by supplementing an M1R selective antagonist
(i.e., VU0255035) in a multimodal pharmacological approach
may allow achieving an effective treatment and induce less
adverse effects.
Muscarinic acetylcholine receptors play important roles in
cognitive, motor, behavioral, sensory, and autonomic processes.
Thus, non-selective blockade of mAChRs is associated with
important side effects, including cognitive deficits. While
scopolamine, a non-selective mAChR antagonist, robustly
increased locomotor activity in reserpinized akinetic rats, it
induced learning and memory impairments (Sheffler et al., 2009;
Xiang et al., 2012). Importantly, most cognitive adverse effects
observed with anticholinergic therapies are likely due to the result
of M2R and M3R blockade (Fornari et al., 2000; Wess et al.,
2007). Conversely, the selective M1R blockade has been shown to
exhibit some antiparkinsonian activity, although without the full
efficacy as observed with non-selective anticholinergics (Xiang
et al., 2012; Lv et al., 2017; Chambers et al., 2019). This is probably
due to activation of other mAChRs, which also have important
roles in the motor circuits of the basal ganglia (e.g., M4R). Indeed,
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antagonizing M1R mainly has an excitatory effect on GABAergic
MSNs, but no or only a partial effect at the subthalamic nucleus
and substantia nigra pars reticulata (Xiang et al., 2012; Lv et al.,
2017). Interestingly, mice lacking M1R have increased locomotor
activity (Gerber et al., 2001; Miyakawa et al., 2001). These M1R
KO mice also have increased extracellular dopamine levels in the
striatum, which suggests that inhibiting M1R positively affects PD
treatment (Gerber et al., 2001). Moreover, M1R KO mice were
shown to maintain contextual fear recognition, which indicates
that M1R might not be involved in the initial stability of memory
or in its formation in the hippocampus (Miyakawa et al., 2001;
Anagnostaras et al., 2003). Accordingly, the main benefit to target
M1R over other mAChRs is due to its selective role in controlling
locomotor activity, whereas its input is less critical for cognitive
processes (Miyakawa et al., 2001).
In conclusion, here we demonstrated, for the first time,
an interaction between D2R and M1R. Interestingly, our
results suggest an extensive integration of dopaminergic and
cholinergic neurotransmission systems in the striatum, where
inhibition by DA is predicted to facilitate locomotor activity,
and activation by ACh inhibits locomotion via striatopallidal
MSNs (Di Chiara et al., 1994). Using reserpinized mice as
a model, we demonstrated the effectiveness of a multimodal
treatment, combining a suboptimal dosage of the selective D2R
agonist sumanirole and the M1R-specific antagonist VU0255035.
Overall, further functional exploitation of this novel D2R–M1R
interaction (i.e., identifying the functional fingerprint of this
putative new heterodimer in native tissue) may provide beneficial
opportunities in PD treatment.
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FIGURE S1 | Validation of the anti-D2R and anti-M1R antibodies via double
immunofluorescence staining in mice brains. Images of coronal slices from mice
brains representing the dorsal striatum, corpus callosum and cortex with staining
of D2R-positive cells (green), M1R-positive cells (red) and DAPI-positive nuclei
(blue). Minimal signal intensities were observed with the anti-D2R and anti-M1R
antibodies in the D2R and M1R KO mice, respectively. Data shown are
representative of two independent experiments. Scale bar = 100 µm.
FIGURE S2 | Validation of the anti-D2R and anti-M1R antibodies via Western
Blotting. (A) The anti-D2R antibody used in our study demonstrates specificity for
D2R in striatal tissue. Extracts of the striatum from D2R KO, D2R heterozygous
(HET), and wild-type (WT) CD-1 littermates were loaded on 10% SDS-PAGE. The
anti-α-Tubulin antibody was used to control for equal loading of the samples. (B)
The anti-M1R antibody used in the study demonstrates specificity for M1R in
striatal tissue. Striatal extracts from M1R KO and wild-type (WT) with C57BL/6J
background were loaded on 10% SDS-PAGE. The anti-α-Tubulin antibody was
used to control for equal loading of the samples. kDa = kilodalton.
FIGURE S3 | Sumanirole dosage-response of reserpine-induced motor
disturbances in mice. The mice were treated with VEH (saline and 5% Tween, i.p.),
or 1, 3, or 10 mg/kg SUM (sumanirole, 1, 3, 10 mg/kg, respectively, i.p.) after
reserpine administration (3 mg/kg, s.c., 20.5 ± 2 h), and evaluated via the (A,B)
locomotor activity test, (C) horizontal bar test and (D) for tremulous jaw
movements (TJMs). (A) The total distance traveled (cm) was measured for 85 min.
Results are presented as mean ± SEM (n = 7–8 animals). Statistical significance
was tested using one-way ANOVA, followed by the Dunnett post hoc test, with
VEH, 1 SUM, and 3 SUM compared to 10 SUM animals, ∗∗p ≤ 0.01. (B) The
distance traveled (cm) was measured every 5 min for 85 min. Results are
presented as mean ± SEM (n = 7–8 animals). Statistical significance was tested
using two-way repeated-measures ANOVA followed by the Tukey post hoc test,
with VEH, 1 SUM, and 3 SUM compared to 10 SUM animals, ∗p ≤ 0.05,
∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001 and ∗∗∗∗p ≤ 0.0001. (C) Reserpine-induced catalepsy
in mice evaluated via the horizontal bar test, with cut-off value of 120 s. Results
are presented as mean ± SEM (n = 7–8 animals). Statistical significance was
tested using one-way ANOVA followed by the Tukey post hoc test, ∗∗p ≤ 0.01.
(D) Reserpine-induced orofacial dyskinesia evaluated by TJMs for 10 min. Results
are presented as mean ± SEM (n = 7–8 animals). Statistical significance was
tested using one-way ANOVA followed by the Tukey post hoc test, ∗∗p ≤ 0.01.
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